(S1 (S (S (NP (NP (JJ Novel) (NN signal) (NN transduction) (NN pathway)) (VP (VBN utilized) (PP (IN by) (NP (JJ extracellular) (NN HSP70))))) (: :) (NP (NP (NN role)) (PP (IN of) (NP (NP (JJ toll-like) (NN receptor) (-LRB- -LRB-) (NN TLR) (-RRB- -RRB-) (CD 2)) (CC and) (NP (NN TLR4)))))) (. .)))
(S1 (S (S (NP (JJ Recent) (NNS studies)) (VP (VBP have) (VP (VBN initiated) (NP (NP (DT a) (NN paradigm) (NN shift)) (PP (IN in) (NP (NP (DT the) (NN understanding)) (PP (IN of) (NP (NP (DT the) (NN function)) (PP (IN of) (NP (NP (NN heat) (NN shock) (NNS proteins)) (PRN (-LRB- -LRB-) (NP (NN HSP)) (-RRB- -RRB-)))))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADVP (RB now)) (ADJP (JJ clear)) (SBAR (IN that) (S (NP (NN HSP)) (VP (MD can) (CC and) (VP (VBP do) (VP (VB exit) (NP (JJ mammalian) (NNS cells)))) (, ,) (VP (VBP interact) (PP (IN with) (NP (NP (NNS cells)) (PP (IN of) (NP (DT the) (JJ immune) (NN system)))))) (, ,) (CC and) (VP (VB exert) (NP (JJ immunoregulatory) (NNS effects)))))))) (. .)))
(S1 (S (S (NP (PRP We)) (ADVP (RB recently)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (ADJP (RB exogenously) (VBN added)) (NN HSP70)) (VP (VBZ possesses) (NP (JJ potent) (NN cytokine) (NN activity)) (, ,) (PP (IN with) (NP (DT the) (NN ability) (S (VP (TO to) (VP (VP (VB bind) (PP (IN with) (NP (JJ high) (NN affinity))) (PP (TO to) (NP (DT the) (NN plasma) (NN membrane)))) (, ,) (VP (VB elicit) (NP (DT a) (JJ rapid) (JJ intracellular) (NN Ca-LRB-2+-RRB-) (NN flux))) (, ,) (VP (VB activate) (NP (NN NF-kappaB))) (, ,) (CC and) (VP (VB up-regulate) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (JJ pro-inflammatory) (NNS cytokines))) (PP (IN in) (NP (JJ human) (NNS monocytes))))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Here)) (PP (IN for) (NP (DT the) (JJ first) (NN time))) (, ,) (NP (PRP we)) (VP (VBP report) (SBAR (SBAR (IN that) (S (NP (JJ HSP70-induced) (JJ proinflammatory) (NN cytokine) (NN production)) (VP (VBZ is) (VP (VBN mediated) (PP (IN via) (NP (DT the) (NN MyD88/IRAK/NF-kappaB) (NN signal) (NN transduction) (NN pathway))))))) (CC and) (SBAR (IN that) (S (NP (NN HSP70)) (VP (VBZ utilizes) (NP (CC both) (NP (NP (NN TLR2)) (PRN (-LRB- -LRB-) (NP (NP (NN receptor)) (PP (IN for) (NP (JJ Gram-positive) (NNS bacteria)))) (-RRB- -RRB-))) (CC and) (NP (NP (NN TLR4)) (PRN (-LRB- -LRB-) (NP (NP (NN receptor)) (PP (IN for) (NP (JJ Gram-negative) (NNS bacteria)))) (-RRB- -RRB-)))) (S (VP (TO to) (VP (VB transduce) (NP (PRP$ its) (JJ proinflammatory) (NN signal)) (PP (IN in) (NP (DT a) (JJ CD14-dependent) (NN fashion)))))))))))) (. .)))
(S1 (S (NP (DT These) (NNS studies)) (ADVP (RB now)) (VP (VBP pave) (NP (NP (DT the) (NN way)) (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (ADJP (RB highly) (JJ effective)) (ADJP (ADJP (JJ pharmacological)) (CC or) (ADJP (JJ molecular))) (NNS tools)) (SBAR (WHNP (WDT that)) (S (VP (MD will) (VP (CC either) (VP (VB up-regulate)) (CC or) (VP (VB suppress) (NP (NP (JJ HSP70-induced) (NNS functions)) (PP (IN in) (NP (NP (NP (NP (NP (NNS conditions)) (SBAR (WHADVP (WRB where)) (S (NP (NN HSP70) (NNS effects)) (VP (VBP are) (ADJP (JJ desirable)))))) (PRN (-LRB- -LRB-) (NP (NN cancer)) (-RRB- -RRB-))) (CC or) (NP (NNS disorders))) (SBAR (WHADVP (WRB where)) (S (NP (NN HSP70) (NNS effects)) (VP (VBP are) (ADJP (ADJP (JJ undesirable)) (PRN (-LRB- -LRB-) (NP (NP (NN arthritis)) (CC and) (NP (NN arteriosclerosis))) (-RRB- -RRB-)))))))))))))))))))) (. .)))
